Evidence map›Paper›PMID 41006278›Full record

ArticleNature communications2025

Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance.

James M Harris, James Lok, Nadina Wand, Andrea Magri, Senko Tsukuda, Yanxia Wu, Esther Ng, Daisy Jennings, Badran Elshenawy, Peter Balfe and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. [Clinical significance and occurrence mechanism of hepatitis B virus DNA integration].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James M HarrisNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1880-3496
James LokInstitute of Liver Studies, Kings College London, London, UK.ORCID http://orcid.org/0000-0001-9719-4312
Nadina WandNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-5518-4367
Andrea MagriNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7143-7168
Senko TsukudaChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Yanxia WuOMICS Technology Platforms, Centre for Human Genomics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0006-2226-5757
Esther NgKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Daisy JenningsNuffield Department of Medicine, University of Oxford, Oxford, UK.
Badran ElshenawyNuffield Department of Medicine, University of Oxford, Oxford, UK.
Peter BalfeNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6246-0876
Jane A McKeatingNuffield Department of Medicine, University of Oxford, Oxford, UK. jane.mckeating@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-7229-5886

Funding

Wellcome TrustWellcome Trust (Wellcome) 200838/Z/16/ZWellcome Trust (Wellcome) 225198/Z/22/Z
6 · The paper itself

Abstract

Hepatitis B virus (HBV) is a small DNA virus that establishes chronic infection and drives progressive liver disease and cancer; presenting a global health problem with more than 250 million infections. HBV replicates via an episomal covalently-closed-circular DNA (cccDNA) and integrated viral DNA fragments are linked to carcinogenesis. Current treatments only suppress HBV replication and there is a global initiative to develop genome targeting therapies, including siRNAs, antisense oligonucleotides and epigenetic modifiers specific for HBV cccDNA. However, our knowledge of the cccDNA and integrant transcriptomes is confounded by overlapping viral RNAs. Using targeted long-read sequencing we mapped the HBV transcriptome in liver biopsies from eleven treatment naïve patients. Probe enrichment yielded robust sequencing libraries and identified cccDNA-derived genomic and sub-genomic transcripts, and a repertoire of previously uncharacterised spliced, truncated and chimeric viral RNAs. Assigning viral transcripts to their respective DNA templates revealed differential promoter activity in cccDNA and integrants, with implications for the efficacy of epigenetic modifiers. Integrant-derived transcripts showed vast diversity in the viral-host junctions, posing a challenge for current nucleotide-targeting therapies. cccDNA was a source of genetic polymorphism, with distinct viral lineages present in the surface antigen encoding region, providing an insight into hepadnavirus evolution during chronic infection.

Indexed as

Drug Resistance, ViralHepatitis BHepatitis B virusPlasmidsTranscriptomeAntiviral AgentsDNA, CircularDNA, ViralFemaleGenome, ViralHepatitis B, ChronicHumansLiverPromoter Regions, GeneticRNA, ViralVirus IntegrationAntiviral AgentsDNA, CircularDNA, ViralRNA, Viral

Identifiers

PMID41006278
PMCPMC12474897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.